2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Creative Media & Community Trust Corporation (CMCT) reported a second-quarter 2026 net loss attributable to common stockholders of $11.0 million, or $4.03 per diluted share, compared with $14.3 million a year earlier. Total revenues were $29.7 million, roughly flat year over year, while total segment net operating income fell 5.2% to $9.3 million. The company also said it elected not to invest the capital needed to refinance the Oakland Office Building mortgage, which had an outstanding balance of $97.1 million and matured in the third quarter of 2026.
Net loss attributable to common stockholders was $11.0 million for the quarter ended June 30, 2026, versus $14.3 million in the same period of 2025.
FFO was $(3.5) million and Core FFO was $(3.4) million, compared with $(7.9) million and $(7.0) million a year earlier.
Total segment NOI decreased 5.2% to $9.3 million, while NOI excluding loss from unconsolidated entities rose 22.2% to $12.5 million.
The $97.1 million non-recourse mortgage on the Oakland Office Building matured in the third quarter of 2026; the company continues to engage with the servicer on a long-term resolution.
Circle8 Group said on August 10, 2026 that it signed a settlement with SPP Credit Advisors that resolves pending New York and Delaware litigation and cancels its $35 million convertible seller's note. The company will issue 21,983,926 shares to SPP, while it gains an option to buy and retire the same number of shares for $0.00001 each, and SPP's remaining debt is to be repaid over an 18-month share disposition period. Separately, Nasdaq notified the company on August 13, 2026 that its stock has closed below $1.00 for 30 consecutive business days.
The $35,000,000 convertible promissory note is released, canceled and discharged; SPP indebtedness was $62,669,730.00 as of August 7, 2026, bearing 5% interest during the disposition period.
Atlantic agrees to issue 21,983,926 shares to SPP, with a ten-year call option to buy the same number of shares at $0.00001 per share for retirement.
Lyneer Staffing agreed to seek refinancing of its SLR facility within 45 days of August 7, 2026, with a $5 million payment to SPP upon refinancing.
Nasdaq's August 13, 2026 letter cites a $1.00 minimum bid price; the filing lists February 9, 2026 as the regain-compliance date and says the stock will continue to trade as CIRC.
REalloys reported second-quarter 2026 net revenues of $0.8 million, up from $0.4 million a year earlier, but its net loss widened to $36.8 million, or $0.59 per diluted share, from $2.2 million, or $0.05 per share. The company said the increase was driven mainly by $32.1 million of non-cash stock-based compensation, and it ended the quarter with $122.4 million in cash, which it says covers its committed strategic project funding without additional financing.
Net revenues were $0.8 million for the quarter ended June 30, 2026, compared with $0.4 million a year earlier.
Net loss was $36.8 million, or $0.59 per diluted share, versus $2.2 million, or $0.05 per share, in the prior-year quarter.
Non-cash stock-based compensation of $32.1 million was the main driver of the higher loss.
Cash was $122.4 million at June 30, 2026, after a $100.0 million private placement closed in June 2026; Craig Cunningham became Chief Financial Officer effective June 24, 2026.
Dawson Geophysical reported unaudited second-quarter 2026 revenue of $17.9 million, up 82% from a year earlier, but a net loss of $3.4 million, or $0.11 per share, which was wider than the $2.3 million loss in the second quarter of 2025. The loss included $1.7 million of strategic transaction costs tied to discussions with controlling stockholder Wilks Brothers, LLC, which the filing says controls about 80% of the common stock. There is no guarantee a definitive agreement will be reached, and a special committee of independent directors is evaluating any such transaction.
Second-quarter fee revenue was $14.0 million, up 60%; total revenue was $17.9 million, up 82% from $9.9 million.
Second-quarter net loss was $3.4 million, or $0.11 per share, including $1.7 million of strategic transaction costs; Adjusted EBITDA was $0.6 million versus negative $1.2 million a year earlier.
Six-month net income was $4.2 million, or $0.14 per share, including $2.4 million of strategic transaction costs.
Discussions with Wilks Brothers, LLC and its affiliates on possible transactions are ongoing; no definitive agreement has been reached.
MapLight agreed to sell 9,197,887 shares and pre-funded warrants for 3,983,168 shares to institutional investors at $11.38 per share, for gross proceeds of approximately $150.0 million before fees, with closing expected on August 14, 2026. The company also reported a second-quarter net loss of $60.2 million, up from $29.8 million a year earlier, and says the financing and existing cash of $351.3 million should fund its lead program through 2028, which means existing shareholders will be diluted.
Private placement of 9,197,887 common shares and pre-funded warrants for 3,983,168 shares at $11.38 per share; gross proceeds of approximately $150.0 million before fees
Expected closing on August 14, 2026; placement agents are Morgan Stanley, Jefferies, Leerink Partners and Stifel
Q2 2026 net loss of $60.2 million vs. $29.8 million in Q2 2025; R&D expenses rose to $53.4 million from $26.8 million
Cash, cash equivalents and investments of $351.3 million at June 30, 2026; company expects runway through 2028 including the private placement proceeds
Calidi Biotherapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $4.2 million, or $2.94 per share, compared with $5.7 million, or $31.75 per share, a year earlier; per-share figures reflect a 1-for-16 reverse split completed in July 2026. Cash fell to $4.1 million by June 30, 2026, and the company's filing lists the risk that it may not raise sufficient capital, which matters for shareholders.
Net loss attributable to common stockholders was $4.2 million, or $2.94 per share, for Q2 2026, versus $5.7 million, or $31.75 per share, in Q2 2025.
General and administrative expenses were $1.6 million, down from $3.1 million; research and development expenses were $2.6 million, unchanged year over year.
Cash was $4.1 million at June 30, 2026, down from $5.6 million at December 31, 2025.
The FDA gave positive pre-IND feedback on CLD-401, and the company targets first patient dosing in Q1 2027.
KIDZ AI Inc. reported second quarter 2026 results for the period ended June 30, 2026. Service revenue fell about 34% year over year to about $0.48 million, while the net loss narrowed 35% to about $2.50 million, and the company said the revenue decline reflects a shift of focus toward its AI infrastructure build-out, where AI compute revenue has not yet started.
Service revenue was about $0.48 million, versus about $0.73 million in the prior year period, a decrease of about 34%.
Net loss was about $2.50 million, versus about $3.87 million a year earlier; gross margin was 44%, consistent with the prior year quarter.
Cash and restricted cash were about $8.88 million at June 30, 2026, up from about $2.75 million at December 31, 2025.
Convertible notes payable fell from about $8.20 million to about $0.67 million since year-end, primarily through conversions to equity.
XBP Global reported second quarter 2026 revenue of $191.3 million, down 14.0% year-over-year on a pro forma basis, and a net loss of $16.7 million. Normalized EBITDA rose 8.4% pro forma to $21.9 million, and the company raised its annualized operational efficiency target to $65 to $75 million from $55 to $60 million. The company also said it has engaged a financial advisor in connection with previously announced strategic alternatives.
Revenue of $191.3 million, down 14.0% year-over-year on a pro forma basis
Net loss of $16.7 million; Normalized EBITDA of $21.9 million, up 8.4% pro forma
Adjusted gross margin of 24.9%, described by the company as its highest level to date
Efficiency target raised to $65 to $75 million annualized, with approximately $35 million expected in 2026
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up from $12.6 million a year earlier, mainly due to a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability tied to its September 2025 private placement. Revenue rose to $1.8 million from $1.5 million, and the company said its cash is sufficient to fund planned activities through the end of 2028.
Net loss for the quarter ended June 30, 2026, was $33.5 million, compared with $12.6 million a year earlier.
Research and collaboration revenue was $1.8 million, up from $1.5 million; R&D expenses were $10.8 million and G&A expenses were $4.3 million.
Cash and cash equivalents were $86.4 million at June 30, 2026, down from $109.5 million at December 31, 2025; the company closed a second private placement tranche raising $50.1 million after quarter-end.
Regulatory clearance was received in Australia and Argentina for a Phase 1/2 trial of CMP-002, with trial launch expected in Q4 2026.
Roadzen reported revenue of $16.2 million for the quarter ended June 30, 2026, up 49% from $10.9 million a year earlier and the highest quarterly revenue in company history. The net loss attributable to ordinary shareholders widened to $9.8 million, or $(0.12) per share, from $4.0 million, or $(0.05) per share, mainly due to a $7.2 million non-cash fair-value loss, while the Adjusted EBITDA loss narrowed to $0.37 million.
Revenue of $16.2 million, up from $10.9 million in the prior-year quarter, an increase of 49%
Net loss attributable to ordinary shareholders of $9.8 million, or $(0.12) per share, versus $4.0 million, or $(0.05) per share, a year earlier; includes a $7.2 million non-cash fair-value loss
Adjusted EBITDA loss of $0.37 million versus $1.41 million a year earlier, the eighth consecutive quarter of improvement
On July 9, 2026, the company signed a definitive agreement to acquire a European MGA with approximately $18–20 million in expected annual revenue
Xos reported second-quarter 2026 revenue of $4.7 million, down from $18.4 million a year earlier, while gross margin rose to 12.1% and net loss narrowed to $6.9 million. The company is revising its 2026 outlook, citing shifted second-half product mix and volume, and says second-quarter deliveries moved into later quarters.
Q2 2026 revenue was $4.7 million on 30 units, versus $18.4 million on 135 units in Q2 2025
Q2 2026 net loss was $6.9 million, compared with $7.5 million in Q2 2025; GAAP operating loss widened to $7.9 million from $7.1 million
Revised 2026 outlook: revenue of $35 to $43 million, non-GAAP operating loss of $(14.7) million to $(11.4) million, and 250 to 350 unit deliveries
Cash and cash equivalents were $13.2 million at June 30, 2026, up from $9.8 million at March 31, 2026
Veritone reported second-quarter 2026 revenue of $24.3 million, up 4.6% from a year earlier, while its operating loss widened 16.4% to $22.1 million, including $4.5 million in restructuring expenses. Net loss narrowed to $22.2 million, mainly due to lower interest expense, and the company is targeting $3.5 million to $8.5 million in additional cost reductions by year-end 2026. For shareholders, revenue and full-year guidance point up, but gross margin fell and the operating loss grew.
Q2 2026 revenue was $24.3 million, up $1.1 million from Q2 2025; Annual Recurring Revenue was $62.0 million, up 0.2%.
Operating loss was $22.1 million versus $19.0 million a year earlier; net loss was $22.2 million versus $26.5 million, helped by $3.2 million lower interest expense.
GAAP gross margin fell to 58.5% from 67.5%, and total Software Products & Services customers declined 7.7% to 2,829.
Full-year 2026 outlook: revenue of $100 million to $115 million versus $92.6 million in fiscal 2025; non-GAAP net loss of $22.0 million to $32.0 million versus $40.8 million.
NextPlat reported second-quarter 2026 revenue of $11.9 million, down from $13.2 million a year earlier but up 21% from the first quarter. The net loss narrowed to $144,000, or $0.05 per diluted share, from $1.8 million, or $0.69 per share, in the prior-year quarter. The company's gross margin of about 40% was a record, but the filing gives no revenue or earnings guidance figures.
Revenue was $11.9 million, down from $13.2 million a year earlier and up about 21% from $9.9 million in the first quarter of 2026.
Gross margin was about 40%, a record, compared with 22% in the second quarter of 2025.
Net loss attributable to common stockholders was $144,000, or $0.05 per diluted share, versus $1.8 million, or $0.69 per share, a year earlier; the company cites about $0.5 million in one-time professional fees.
Cash was $11.9 million at June 30, 2026, with no material unsecured debt; the company also announced an intended acquisition of a pharmacy operation in the Pensacola area.
QXO reported second-quarter 2026 results for the three months ended June 30, 2026. Net sales rose to $3,246 million from $1,906 million a year earlier, and the company said the increase includes $595 million attributable to the Kodiak business acquired April 1, 2026, but GAAP net loss was $55 million versus $59 million, while Adjusted Diluted EPS fell to $0.08 from $0.11.
Net sales were $3,246 million for the quarter, up from $1,906 million, including $595 million from Kodiak.
Basic and diluted loss per share was $(0.14), compared with $(0.15) a year earlier.
Adjusted EBITDA was $272 million, up from $204 million, and Adjusted Diluted EPS was $0.08, down from $0.11.
The TopBuild acquisition was completed on July 1, 2026, after the quarter ended.
AmpliTech Group reported unaudited second-quarter 2026 revenue of $8.07 million, up about 50.9% from $5.35 million in the first quarter, and gross profit of $2.25 million, up 161.2% year over year. The net loss widened to $3.09 million from $1.77 million a year earlier as research and development and selling, general and administrative spending increased. Shareholders also saw the July 22, 2026 close of the Series A Rights process, which brought approximately $20.12 million in net proceeds.
Q2 2026 revenue was $8.07 million, versus $5.35 million in Q1 2026.
Gross margin was 27.9%, compared with 48.0% in Q1 2026 and 7.8% in Q2 2025.
Net loss was $3.09 million, versus $1.77 million in Q2 2025; R&D expense was $1.37 million.
Series A Rights closed July 22, 2026, with approximately $21.92 million gross and $20.12 million net proceeds.
Elutia reported second quarter 2026 results with net sales down to $2.4 million from $2.7 million, while its net loss narrowed to $7.6 million from $9.6 million. The company said it has secured up to $26 million in additional capital to fund NXT-41x through anticipated FDA clearance and its first full year of commercial launch, without an equity offering, which matters to shareholders because it reduces near-term dilution risk.
Q2 2026 net sales were $2.4 million versus $2.7 million a year earlier, due mainly to a $0.7 million reduction in SimpliDerm revenue from a contract manufacturer production disruption.
Adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million in the prior-year quarter.
Up to $26 million of capital includes a $15 million credit facility ($10 million funded at closing) and up to $11 million from the SimpliDerm divestiture.
Cash and cash equivalents were $19.9 million at June 30, 2026, and the company expects the full $8 million BioEnvelope escrow to be released in the fourth quarter of 2026.
Fortress Biotech reported second quarter 2026 net revenue of $18.7 million, up 14% from $16.4 million a year earlier, and a net loss attributable to common stockholders of $2.5 million, or $0.08 per share, compared with net income of $13.4 million, or $0.50 per share basic, in the second quarter of 2025. Operating expenses fell sharply, with research and development at $0.8 million versus $8.1 million and selling, general and administrative costs at $20.8 million versus $38.8 million, and cash and cash equivalents rose to $196.6 million as of June 30, 2026 from $79.4 million at December 31, 2025.
Net revenue was $18.7 million for the quarter, of which $17.8 million came from marketed dermatology products, compared with $16.4 million a year earlier.
Loss from operations narrowed to $10.0 million from $36.5 million, driven mainly by lower SG&A and R&D expenses.
Net loss attributable to common stockholders was $(2.5) million, or $(0.08) per share, versus net income of $13.4 million, or $0.50 per share basic, in the prior-year quarter.
Partner Crystalys Therapeutics announced a $130 million Series B financing in July 2026 for dotinurad, on which subsidiary Urica is entitled to a 3% royalty on future net sales.
Cineverse reported results for the fiscal first quarter ended June 30, 2026. Revenue rose 175% to $30.6 million, mainly from the Giant Worldwide and IndiCue acquisitions, but the net loss attributable to common stockholders widened to $5.8 million, or $0.28 per share, from $3.6 million, or $0.21 per share, a year earlier. The company reaffirmed its full fiscal 2027 guidance of $115 to $120 million in revenue and $10 to $20 million in Adjusted EBITDA.
Revenue was $30.6 million versus $11.1 million in the prior-year quarter, a 175% increase.
Net loss attributable to common stockholders was $(5.8) million, or $(0.28) per share, versus $(3.6) million, or $(0.21) per share.
Adjusted EBITDA was $0.5 million, an increase of $2.6 million over the prior year.
Full fiscal 2027 guidance was reaffirmed at $115 to $120 million in revenues and $10 to $20 million in Adjusted EBITDA.
Trust Stamp reported results for the six months ended June 30, 2026, with net recognized revenue up 22% to $1.66 million. The net loss rose 27.29% to $4.93 million, and total operating expenses increased to $6.32 million, so higher revenue came with a larger loss for shareholders.
Net recognized revenue for the six months ended June 30, 2026 was $1.66 million, up 22% from $1.36 million, driven mainly by the S&P 500 bank customer and $192 thousand billed in Q2 for telecom work.
Net loss was $4.93 million versus $3.87 million a year earlier; basic and diluted loss per share was $0.90 compared with $1.57.
Total operating expenses were $6.32 million versus $5.20 million, including $1.42 million of non-cash expenses; cash and cash equivalents were $6.31 million at June 30, 2026.
Negotiations continue with a second African telecoms company and on three government-related contracts in Ghana, which the company expects to result in one or more definitive agreements during FY 2026.
Invivyd reported second-quarter 2026 PEMGARDA net product revenue of $14.3 million, up 21% from $11.8 million a year earlier. Net loss grew to $44.4 million, or $0.14 per share, from $14.7 million, or $0.12 per share, as R&D and SG&A expenses rose sharply for the VYD2311 clinical trials and commercial activities, which matters to shareholders because the company's cash of $160.1 million is expected to fund operations through the DECLARATION pivotal data readout.
Q2 2026 R&D expenses were $29.4 million, up from $9.6 million, mainly from DECLARATION and LIBERTY trial costs.
Q2 2026 SG&A expenses were $29.5 million, up from $16.6 million.
Cash and cash equivalents were $160.1 million as of June 30, 2026.
In July 2026, Invivyd received twelve months' advance notice of the termination of the PEMGARDA emergency use authorization.
Laird Superfood reported second quarter 2026 net sales of $41.3 million, up 244% from $12.0 million a year earlier, driven largely by the Navitas and Terrasoul acquisitions. The company's net loss widened to $1.8 million, or $0.25 per share, from $0.4 million, or $0.03 per share, mainly due to acquisition and integration costs; the company reaffirmed its full-year 2026 guidance.
Q2 net sales $41.3 million vs. $12.0 million in the prior-year quarter; gross margin 30.3% vs. 39.9%
Net loss $1.8 million, or $0.25 per share, vs. $0.4 million, or $0.03 per share; adjusted EBITDA $3.0 million vs. $0.1 million
Full-year 2026 guidance reaffirmed: net sales of $138 to $148 million and adjusted EBITDA of $8 to $12 million
Cash totaled $23.2 million at June 30, 2026, with no outstanding debt
Merlin reported second quarter 2026 revenue of $2.2 million and a GAAP net loss of $58.4 million, compared with $1.0 million of revenue and a $90.4 million net loss in the first quarter. Year over year, revenue fell from $3.1 million and the net loss widened from $16.3 million, and the Adjusted EBITDA loss grew sequentially to $27.8 million from $23.3 million. Cash, cash equivalents, and short-term investments rose to $183.9 million with no debt, and the net loss attributable to common stockholders was $127.5 million after preferred stock charges.
Q2 2026 revenue was $2.2 million, up from $1.0 million in Q1 2026 and down from $3.1 million in Q2 2025.
GAAP net loss was $58.4 million, versus $90.4 million in Q1 2026 and $16.3 million in Q2 2025.
Adjusted EBITDA loss was $27.8 million, versus $23.3 million in Q1 2026.
Cash, cash equivalents, and short-term investments were $183.9 million at June 30, 2026, up from $123.1 million at March 31, 2026, and the company reported no debt.
Eledon Pharmaceuticals reported a second-quarter 2026 net loss of $31.6 million, or $0.27 per share, compared with $11.2 million, or $0.13 per share, a year earlier. The loss was driven largely by a $9.6 million non-cash charge from changes in warrant liabilities; excluding that item, the net loss was $22.0 million versus $23.5 million. Cash and short-term investments fell to $88.8 million, which the company expects to fund operations into the second quarter of 2027.
Q2 2026 net loss $31.6 million ($0.27 per share) vs. $11.2 million ($0.13 per share) in Q2 2025
Non-cash warrant liability loss of $9.6 million in Q2 2026 vs. a $12.3 million gain in Q2 2025
Excluding warrant items, net loss was $22.0 million vs. $23.5 million
Cash, cash equivalents and short-term investments were $88.8 million at June 30, 2026, funding operations into Q2 2027
Caribou Biosciences reported a second-quarter 2026 net loss of $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, a year earlier. The prior-year figure included $21.3 million in non-cash impairment charges, and licensing and other third-party revenue fell to $1.5 million from $2.7 million. The company now expects its cash to fund its current operating plan to the end of 2027, but cash, cash equivalents, and marketable securities declined to $113.8 million as of June 30, 2026, and the company said it is exploring options to fully fund its planned ANTLER-3 trial.
Net loss of $24.3 million, or $0.24 per share, for the quarter ended June 30, 2026, versus $54.1 million, or $0.58 per share, a year earlier
Licensing and other third-party revenue of $1.5 million, down from $2.7 million in the same period of 2025
Cash, cash equivalents, and marketable securities of $113.8 million at June 30, 2026, down from $142.8 million at December 31, 2025
Cash now expected to fund the current operating plan to the end of 2027; the company is exploring multiple options to fully fund the ANTLER-3 trial
MacroGenics reported second-quarter 2026 revenue of $32.8 million, up from $6.9 million a year earlier, and net income of $19.5 million, compared with a net loss of $36.3 million. The profit reflects $89.2 million of income from discontinued operations tied to the sale of its manufacturing operations, while the loss from continuing operations widened to $69.6 million, including a $52.8 million non-cash loss on extinguishing a royalty monetization liability.
Q2 2026 total revenue was $32.8 million, versus $6.9 million in Q2 2025, driven mainly by a $24.5 million Sanofi regulatory milestone.
Net income was $19.5 million, or $0.31 per share, versus a net loss of $36.3 million, or $0.57 per share, a year earlier.
Loss from continuing operations was $69.6 million, compared with $42.7 million a year earlier, after a $52.8 million non-cash loss on extinguishment of the ZYNYZ royalty monetization liability.
Pro forma cash, cash equivalents and marketable securities were $327 million, and the company guides cash runway through 2028.
Midera Food Processing reported results for the quarter ended July 4, 2026, its first report as an independent public company after its separation from The Middleby Corporation on July 6, 2026. Net sales rose 13.2% and orders rose 16%, and the company raised full-year 2026 guidance, but net earnings fell to $10.8 million from $29.1 million a year earlier. The Board also authorized a share repurchase program of up to $50 million.
Net sales were $245.4 million, up 13.2% from $216.7 million; organic net sales grew 1.2%.
Net earnings were $10.8 million, compared with $29.1 million in the prior year quarter.
Full-year 2026 net sales guidance was raised to $935 million-$965 million from $915 million-$945 million; Estimated Standalone Adjusted EBITDA guidance is $160 million-$176 million.
On August 10, 2026, the Board authorized repurchases of up to $50 million of common stock, expiring August 10, 2029.
TSS, Inc. reported results for the three and six months ended June 30, 2026. Second-quarter revenue fell 20% to $35.1 million, while gross profit and adjusted EBITDA rose, and net income and diluted EPS declined slightly. The company maintained its 2026 adjusted EBITDA outlook at the upper end of its $20 million to $22 million range.
Q2 revenue of $35.1 million, down 20%; systems integration revenue rose 46% to $13.9 million, or 39% of total revenue
Net income of $1.4 million and diluted EPS of $0.05, versus $1.5 million and $0.06 in the year-earlier quarter
Gross profit of $8.0 million, up 11%; adjusted EBITDA of $4.5 million, up 12%
2026 adjusted EBITDA outlook maintained at the upper end of the $20 million to $22 million range
ProMIS Neurosciences reported a net loss of $11.7 million, or $1.28 per share, for the quarter ended June 30, 2026, up from a $10.1 million loss a year earlier. Cash and short-term investments were $53.4 million, which the company says will fund operations through 2027, past the expected first quarter 2027 topline readout from its PRECISE-AD trial. Per-share loss narrowed mainly because of more weighted-average shares after a January 2026 financing.
Q2 2026 net loss was $11.7 million ($1.28 per share), versus $10.1 million ($7.26 per share) in Q2 2025
Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at December 31, 2025
The increase reflects $70.1 million in net proceeds from a January 2026 private placement, in which certain directors and management participated
Unblinded 12-month PRECISE-AD topline data is expected in the first quarter of 2027
York Space Systems reported second-quarter 2026 revenue of $92.5 million, up 10% from a year earlier, and gross profit of $22.2 million, up from $9.5 million. Net loss widened to $39.3 million from $24.2 million, and the company lowered its full-year 2026 revenue outlook to $375 million to $405 million, citing the removal of new business revenue from 2026 due to a shift in government acquisition methods. The guidance cut lowers the revenue outlook for shareholders, while the quarter's revenue and gross profit gains partly offset the wider loss.
Q2 2026 revenue was $92.5 million, up 10%; gross profit was $22.2 million, up from $9.5 million, and gross margin rose to 24%.
Q2 2026 net loss was $39.3 million, up 62% from $24.2 million; six-month net loss was $154.2 million.
Full-year 2026 revenue guidance is $375 million to $405 million, which the company said reflects removing new business revenue due to a shift in government acquisition methods.
Backlog was $592.0 million at June 30, 2026, down 8% from $642.3 million on March 31, 2026.
Elicio Therapeutics reported a second-quarter 2026 net loss of $8.2 million, down from $10.6 million a year earlier, and said its Phase 2 AMPLIFY-7P trial of ELI-002 7P did not meet its primary endpoint. The company plans a Phase 1 combination study in metastatic pancreatic cancer, anticipated to start in Q4 2026, and says its cash will support operations into the first quarter of 2027.
Net loss for Q2 2026 was $8.2 million, or $0.43 per share, versus $10.6 million, or $0.66 per share, in Q2 2025.
Cash and cash equivalents were $23.5 million as of June 30, 2026; a July 2026 registered direct offering raised approximately $15.0 million gross.
The Phase 2 AMPLIFY-7P trial did not meet its primary endpoint; the company continues to evaluate pre-specified subgroups, including the R0 resected population.
The Phase 1 combination study is anticipated to begin in Q4 2026.
On August 13, 2026, Lithium Americas completed the initial closing of a $150.0 million subordinated convertible debenture sale to YA II PN, Ltd., with a further $25.0 million available through delayed closings at the company's option. The debentures can convert into common shares at a discount to market price, and conversion is capped at 19.99% of outstanding shares unless stockholders approve a higher limit, so the deal could dilute existing shareholders while adding funding.
$150.0 million of debentures issued August 13, 2026 at 100% of principal, with a 5-year maturity and 5% annual interest
Conversion price is the lower of $4.56 or 95% of the lowest five-day VWAP, with a floor of $1.63 that can fall to $0.65 in certain circumstances
Cash principal repayments are capped at $35 million while Orion notes remain outstanding
Remaining $25.0 million may be sold in delayed closings upon exercise of the company's put right
Serina Therapeutics reported second quarter 2026 results with a net loss attributable to common shareholders of $8.9 million, up from $6.6 million a year earlier, while the per-share loss narrowed to $(0.55) from $(0.66) on a larger share count. The company said it completed enrollment and dosing in Cohort 1 of the SER-252 Phase 1b registrational study in July 2026, ahead of its prior guidance, with top-line data still targeted for the first half of 2027.
Net loss attributable to common shareholders was $8.9 million, or $(0.55) per share, for Q2 2026, versus $6.6 million, or $(0.66) per share, for Q2 2025.
No revenue was reported in Q2 2026, compared with $130 thousand in Q2 2025; total operating expenses rose to $6.8 million from $5.7 million.
Cash and cash equivalents totaled $23.0 million as of June 30, 2026.
Cohort 1 of SER-252 completed enrollment and dosing in July 2026, ahead of guidance for the end of Q3 2026; top-line data are targeted for the first half of 2027.
Jefferson Capital reported second quarter 2026 revenue up 16.2% to a record $177.5 million, but net income fell 13.4% to $41.3 million as operating expenses rose 45.6% to $95.4 million. The company also declared a quarterly cash dividend of $0.24 per share, and the results show revenue growth offset by lower profit for shareholders.
Collections rose 17.7% to $300.9 million and deployments rose 21.5% to $152.2 million in the quarter.
Net income was $41.3 million versus $47.7 million a year earlier; diluted EPS was $0.67.
Operating expenses increased $29.9 million, including $8.3 million of non-cash stock-based compensation.
Quarterly dividend of $0.24 per share is payable September 3, 2026, to holders of record on August 24, 2026.
HawkEye 360 reported second-quarter 2026 revenue of $49.8 million, up 87% from the prior-year period, but posted a net loss of $15.3 million compared with net income of $1.6 million a year earlier. The company also said all shares subject to IPO lock-up agreements will become eligible for sale in the public market on September 2, 2026, which could add selling pressure for shareholders.
Q2 2026 revenue of $49.8 million, up from $26.6 million; international revenue was $21.0 million, up 134%.
Net loss of $15.3 million versus net income of $1.6 million in Q2 2025; Adjusted EBITDA was $7.0 million versus $7.8 million.
Full-year 2026 outlook: total revenue of $215.0 million to $220.0 million and Adjusted EBITDA of $30.0 million to $36.0 million.
Lock-up shares become eligible for sale on September 2, 2026, subject to affiliate trading limits and the company's insider trading policies.
Aktis Oncology reported second-quarter 2026 results for the period ended June 30, 2026. Collaboration revenue rose to $3.4 million from $1.6 million, but higher research and development and general and administrative spending widened the net loss to $24.1 million from $18.1 million, and the company's cash position rose to $517.3 million after its January 2026 initial public offering.
Net loss was $24.1 million for the quarter, compared with $18.1 million a year earlier.
Collaboration revenue was $3.4 million, compared with $1.6 million a year earlier, tied to the Eli Lilly and Company research collaboration.
Research and development expenses rose to $25.3 million from $18.6 million, and general and administrative expenses rose to $7.0 million from $3.9 million.
Cash, cash equivalents, and marketable securities were $517.3 million at June 30, 2026, which the company says will fund its operating plan into 2029.
ARS Pharma reported second quarter 2026 results and outlined a narrower commercial strategy focused on high-volume prescribers. Total revenue rose to $33.7 million from $15.7 million a year earlier, but the net loss widened to $62.3 million, or $0.63 per share, from $44.9 million, or $0.46 per share. The company expects second-half 2026 SG&A and R&D expenses of $114 million to $126 million and a path to cash flow breakeven by the end of 2027.
Total revenue of $33.7 million in Q2 2026, including $26.2 million of U.S. neffy net product revenue, versus $15.7 million in Q2 2025.
Net loss of $62.3 million, or $0.63 per share, versus $44.9 million, or $0.46 per share, in Q2 2025.
Second-half 2026 SG&A and R&D expenses guided to $114 million to $126 million, including stock-based compensation; cash-based expenses guided to $100 million to $110 million.
Cash, cash equivalents and short-term investments of $143.8 million as of June 30, 2026; Meg Smith joins as Chief Commercial Officer effective August 17, 2026.
Smith Micro reported second-quarter 2026 revenue of $4.3 million, down from $4.4 million a year earlier, while gross profit rose to $3.5 million from $3.2 million. GAAP net loss attributable to common stockholders narrowed to $2.7 million, or $0.52 per share, from $15.1 million, or $3.88 per share, a year earlier, a period that included an $11.1 million goodwill impairment. Shareholders should note the mixed picture: revenue declined slightly while losses narrowed, and cash and cash equivalents were $2.8 million as of June 30, 2026.
Q2 2026 revenue was $4.3 million versus $4.4 million in Q2 2025; six-month revenue was $8.6 million versus $9.0 million.
Q2 2026 GAAP net loss attributable to common stockholders was $2.7 million, or $0.52 per share, versus $15.1 million, or $3.88 per share, in Q2 2025.
Non-GAAP net loss attributable to common stockholders was $1.0 million, or $0.19 per share, versus $2.8 million, or $0.71 per share, a year earlier.
A one-for-five reverse stock split became effective June 4, 2026; per-share figures are adjusted for it.
Heartflow reported second-quarter 2026 revenue of $64.1 million, up 48% from a year earlier, and raised its full-year 2026 revenue guidance to $246 million to $250 million from $228 million to $232 million. GAAP net loss widened to $15.7 million from $9.2 million, though the prior-year period benefited from non-operating gains, and the per-share loss narrowed to $0.18 from $1.46 on a much larger share count. Shareholders get faster sales growth and a higher guidance range, offset by a larger GAAP operating loss.
Total revenue of $64.1 million, up 48%; U.S. revenue of $59.6 million and international and other revenue of $4.5 million
Gross margin of 83.0%, compared with 75.5% a year earlier
GAAP net loss of $15.7 million, or $(0.18) per share, compared with $9.2 million, or $(1.46) per share, a year earlier; operating loss widened to $17.9 million from $13.7 million
2026 revenue guidance raised to $246 million to $250 million from $228 million to $232 million; non-GAAP gross margin guidance raised to about 82% from about 81%
American Shared Hospital Services reported second-quarter 2026 revenue of $8.4 million, up 19% from a year earlier, while its net loss attributable to the company widened to $514,000, or $0.07 per diluted share, from $280,000, or $0.04 per share. After quarter end, the company entered a Third Amendment to its Credit Agreement and Forbearance Agreement with Fifth Third Bank and secured $2.0 million of subordinated financing from an entity controlled by its Executive Chairman.
Q2 revenue was $8.4 million, up from $7.1 million; Direct Patient Services revenue rose 40% to $4.9 million.
Q2 net loss attributable to the company was $514,000 ($0.07 per diluted share), versus $280,000 ($0.04) in Q2 2025, driven by $285,000 of legal costs and a $909,000 increase in credit loss allowance.
Subsequent to quarter end, the company signed a Third Amendment to its Credit Agreement and Forbearance Agreement with Fifth Third Bank.
The company secured $2.0 million of subordinated financing from RCS/TIG Holdings LLC, an entity controlled by Executive Chairman Ray Stachowiak.
Ideal Power reported results for the three months ended June 30, 2026. Revenue was $5,800, up from $1,275 a year earlier, but the net loss widened to $3.4 million from $3.0 million, while the per-share loss narrowed to $0.20 from $0.33 after a larger share count. The company ended the quarter with $41.3 million in cash and no long-term debt, following $27.7 million in net proceeds from a registered direct offering.
Q2 2026 revenue was $5,800 versus $1,275 in Q2 2025.
Net loss was $3.4 million in Q2 2026 versus $3.0 million in Q2 2025; operating expenses rose to $3.6 million from $3.1 million.
Net loss per share was $0.20 versus $0.33, on 16,934,431 weighted average shares versus 9,116,519.
Cash and cash equivalents were $41.3 million at June 30, 2026, including $27.7 million in net proceeds from a registered direct offering during the quarter.
Bit Digital reported second quarter 2026 revenue of $32.1 million, up 15% from $27.9 million in the first quarter, and a net loss attributable to shareholders of $(107.2) million, or $(0.31) per diluted share, compared with $(146.7) million, or $(0.45) per share, in the prior quarter. The company said non-cash movements on digital assets and non-operating items accounted for about $86 million of the quarterly loss, and it raised $50 million against its ether treasury to fund a financing facility for its WhiteFiber subsidiary.
Total revenue was $32.1 million for the quarter, up 15% from $27.9 million in the first quarter of 2026.
Net loss attributable to Bit Digital shareholders was $(107.2) million, or $(0.31) per diluted share, versus $(146.7) million, or $(0.45) per share, in the first quarter.
Non-cash movements on digital assets and non-operating items together accounted for about $86 million of the quarterly loss.
CEO Sam Tabar said the Board is evaluating options to address the gap between the company's operating results and its valuation.
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million, up from $18.1 million a year earlier, and a net loss of $16.6 million, or $0.11 per share, down from $56.6 million, or $0.50 per share. The company also said the FDA raised substantial concerns about the benefit-risk of the LOTIS-5 trial after a pre-sBLA meeting, and it is assessing its regulatory path, which affects shareholders' view of the future approval path for ZYNLONTA.
Q2 2026 net product revenue was $18.6 million versus $18.1 million in Q2 2025; six-month revenue was $38.7 million versus $35.5 million.
Q2 2026 net loss was $16.6 million ($0.11 per share) versus $56.6 million ($0.50 per share) a year earlier; total operating expenses fell 29% to $44.7 million.
The FDA noted substantial concerns about the LOTIS-5 benefit-risk profile; the company plans to provide an update on regulatory strategy and timing in the near future.
Cash and cash equivalents were $219.1 million at June 30, 2026, down from $261.3 million at December 31, 2025; the company expects a cash runway at least into 2028.
BK Technologies reported second-quarter 2026 results, with revenue up 11% to $23.4 million and gross margin rising to 51.9%. Net income fell to $3.2 million from $3.7 million a year earlier, mainly because of a $0.6 million higher income tax provision, and diluted EPS dropped to $0.79 from $0.96. The company reiterated its full-year 2026 targets, which include $90 million in revenue and GAAP EPS of over $3.15 per diluted share.
Q2 2026 revenue was $23.4 million, up from $21.2 million in Q2 2025, driven by state and local agency orders.
Net income was $3.2 million, or $0.79 per diluted share, versus $3.7 million, or $0.96 per diluted share, in Q2 2025.
Cash and cash equivalents were $29.9 million at June 30, 2026, and the company reported no debt.
Full-year 2026 targets were reiterated: $90 million revenue, gross margin above 50%, GAAP EPS over $3.15 diluted, and non-GAAP adjusted EPS of $3.55 diluted.
Lifeway Foods reported second-quarter 2026 net sales of $66.9 million, up 24.1% from a year earlier and its highest quarterly total on record. Net income fell to $0.1 million, or $0.01 per diluted share, from $4.3 million, or $0.28 per share, as gross profit margin dropped to 19.5% from 28.6% on higher milk, packaging and transportation costs. Management said it expects gross margin and profitability to fully recover in 2027, but the filing gives no numeric forecast.
Net sales rose 24.1% year-over-year to $66.9 million, $3.9 million above the prior quarterly record.
Net income was $0.1 million, or $0.01 per diluted share, versus $4.3 million, or $0.28 per diluted share, a year earlier.
Gross profit margin fell to 19.5% from 28.6%, which the company attributes mainly to elevated milk prices.
Management expects gross margin and profitability to fully recover in 2027.
HeartCore Enterprises reported second-quarter 2026 results with revenue up 71.6% to $321,000, while the company posted a net loss of $2.0 million, compared with net income of $1.1 million a year earlier. The company also said it completed the divestiture of Sigmaways and agreed to sell its 51% stake in HeartCore Luvina, and that it regained Nasdaq minimum bid price compliance.
Q2 2026 revenue rose to $321,000 from $187,000, driven by software development services, partly offset by lower Go IPO consulting revenue.
Q2 2026 net loss was $2.0 million versus net income of $1.1 million, with gross loss of $70,000 and a shift from other income to other expenses.
Six-month net loss widened to $4.0 million from $2.1 million; cash and cash equivalents were $587,000 as of June 30, 2026.
The company has agreed to divest its 51% equity interest in HeartCore Luvina to Luvina Software Joint Stock Company and completed the Sigmaways divestiture.
Lucid Diagnostics reported second quarter 2026 revenue of $1.5 million, up from $1.2 million a year earlier, and a GAAP net loss attributable to common stockholders of $14.7 million, or $(0.08) per share, compared with $7.9 million in the prior-year quarter. The company also said it secured its first laboratory benefit manager coverage policy for its EsoGuard test, but it still awaits a positive draft Medicare coverage policy.
Q2 2026 revenue was $1.5 million ($1,474 thousand), up from $1,163 thousand in Q2 2025.
GAAP net loss attributable to common stockholders was $14.7 million, or $(0.08) per share, versus $7.9 million a year earlier.
Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share, versus $9.9 million in Q2 2025.
Cash and cash equivalents were $33.4 million at June 30, 2026, compared with $34.7 million at December 31, 2025.
NeuroOne reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Product revenue rose 16% year over year to $2.0 million and product gross margin reached 59.9%, but the net loss widened to $2.0 million from $1.5 million, and cash fell to $2.0 million from $6.6 million at September 30, 2025.
Product revenue was $2.0 million, up from $1.7 million in the year-ago quarter.
Net loss was $2.0 million, or $(0.23) per basic share, versus $1.5 million, or $(0.19) per basic share, a year earlier.
Product orders were $2.7 million in the quarter, and fiscal 2026 product orders to date total $11.2 million.
Cash and cash equivalents were $2.0 million as of June 30, 2026, and the company raised $8.4 million gross through its at-the-market program since the start of the fiscal year (through June 30, 2026).
Duke Robotics reported second-quarter 2026 results, with revenue of $149,000 up from $143,000 a year earlier. The net loss widened to $726,000, or $(0.26) per share, from $269,000, or $(0.12) per share, mainly on higher general and administrative expenses tied to its Nasdaq uplisting, public offering and share-based compensation. Cash rose to $6,989,000 after the May 2026 offering, which raised approximately $9.2 million in gross proceeds, and the company says cash supports operations into 2028.
Q2 2026 revenue was $149,000 versus $143,000 in Q2 2025; gross profit fell to $58,000 from $88,000.
G&A expenses rose to $954,000 from $314,000, including non-recurring professional fees tied to the uplisting and offering.
Net loss was $726,000, or $(0.26) per share, versus $269,000, or $(0.12) per share, a year earlier.
Cash and cash equivalents and restricted cash were $6,989,000 as of June 30, 2026, versus $750,000 at December 31, 2025.
Creative Realities reported second-quarter 2026 revenue of $21.5 million, up from $13.0 million a year earlier, with about $7.4 million coming from the acquired Cineplex Digital Media business. The net loss widened to $4.2 million from $1.8 million, and the net loss attributable to common stockholders was $4.3 million, or $(0.41) per diluted share, compared with $(0.17) a year earlier, so higher sales came with larger losses for shareholders.
Q2 2026 sales of $21.5 million vs. $13.0 million in Q2 2025; about $7.4 million from the CDM acquisition
Net loss attributable to common stockholders of $4.3 million, or $(0.41) per diluted share, vs. $(0.17) a year earlier
Adjusted EBITDA (non-GAAP) of $2.0 million vs. $1.1 million; cash of $10.7 million and debt of $46.6 million at June 30, 2026
Public offering raised net proceeds of approximately $12.2 million; company cites a grocery chain contract estimated above $10 million in aggregate
Intuitive Machines reported second-quarter 2026 revenue of $206 million, up from $50.3 million a year earlier, and ended the quarter with backlog of $1.8 billion. Its net loss widened to $62.8 million, or $0.29 per share, from $38.2 million, or $0.22 per share, so higher sales did not translate into a smaller loss per share for shareholders. The company also set a full-year 2026 revenue outlook of $900 million to $1 billion.
Q2 2026 total revenue of $206.2 million versus $50.3 million in Q2 2025
Net loss of $62.8 million ($0.29 per share) versus $38.2 million ($0.22 per share) a year earlier
Adjusted EBITDA loss narrowed to $13.8 million from $25.4 million in Q2 2025
Backlog of $1.76 billion at June 30, 2026; full-year 2026 revenue outlook of $900 million to $1 billion
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.